Accordingly, adding VEGFA inhibitors or multi-kinase inhibitors such as Sunitinib simultaneously with HIF inhibitor in clinical trials may well suppress angiogenesis of glioblastoma, slow tumor progression, and achieve improved OS. Here, VEGFA is linked to neoplasm.